SPROUTY-2 represses the epithelial phenotype of colon carcinoma cells via upregulation of ZEB1 mediated by ETS1 and miR-200/miR-150

Oncogene

Volumn 35, Issue 23, 2016, Pages 2991-3003

  Barbachano A ^a   Fernandez Barral A ^a   Pereira, F ^a   Segura, M F ^b,g   Ordonez Moran P ^a,h   Carrillo De Santa Pau, E ^c   Gonzalez Sancho J M ^a   Hanniford, D ^b   Martinez N ^d   Costales Carrera, A ^a   Real, F X ^c,e   Palmer H G ^f   Rojas, J M ^d   Hernando, E ^b   Munoz A ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Structural Biology and Biocomputing Programme   (Spain)

^d Unidad Funcional de Investigación en Enfermedades Crónicas   (Spain)

^e UNIVERSITAT POMPEU FABRA   (Spain)

^f VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 7; MICRORNA; MICRORNA 200; OCCLUDIN; SPROUTY 2; SPROUTY PROTEIN; TRANSCRIPTION FACTOR ETS 1; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; ETS1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MIRN150 MICRORNA, HUMAN; MIRN200 MICRORNA, HUMAN; SIGNAL PEPTIDE; SPRY2 PROTEIN, HUMAN; ZEB1 PROTEIN, HUMAN;

ARTICLE; COLON CARCINOMA; COLON MUCOSA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; RNA INTERFERENCE; TIGHT JUNCTION; TRANSCRIPTOMICS; UPREGULATION; CELL ADHESION; CELL POLARITY; CELL PROLIFERATION; COLON TUMOR; EPITHELIUM CELL; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; CELL POLARITY; CELL PROLIFERATION; COLONIC NEOPLASMS; EPITHELIAL CELLS; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICRORNAS; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-ETS-1; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84973863209     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.366     Document Type: Article

References (61)

1. Cabrita MA, Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008; 11: 53-62.
2. Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. Cancer Metastasis Rev 2014; 33: 695-720.
3. Egan JE, Hall AB, Yatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA 2002; 99: 6041-6046.
4. Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S, Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol 2003; 13: 297-307.
5. Wong ES, Fong CW, Lim J, Yusoff P, Low BC, Langdon WY et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J 2002; 21: 4796-4808.
6. Haglund K, Schmidt MH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep 2005; 6: 635-641.
7. Barbachano A, Ordonez-Moran P, Garcia JM, Sanchez A, Pereira F, Larriba MJ et al. SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity. Oncogene 2010; 29: 4800-4813.
8. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: SPROUTY/ c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010; 29: 5241-5253.
9. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al. Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 2011; 47: 1946-1954.
10. Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF et al. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res 2004; 64: 5556-5559.
11. Bloethner S, Chen B, Hemminki K, Muller-Berghaus J, Ugurel S, Schadendorf D et al. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis 2005; 26: 1224-1232.
12. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
13. 3a target gene indicative of poor prognosis in colon cancer. Oncogene 2014; 33: 1975-1985.
14. Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ, Yeh KT et al. Deregulated expression of sprouty2 and microRNA-21 in human colon cancer: correlation with the clinical stage of the disease. Cancer Biol Ther 2011; 11: 111-121.
15. McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, Heer R et al. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 2005; 24: 2166-2174.
16. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006; 66: 2048-2058.
17. Sánchez A, Setien F, Martínez N, Oliva JL, Herranz M, Fraga MF et al. Epigenetic inactivation of the ERK inhibitor Spry2 in B-cell diffuse lymphomas. Oncogene 2008; 27: 4969-4972.
18. Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L et al. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood 2009; 113: 2478-2487.
19. Faratian D, Sims AH, Mullen P, Kay C, Um I, Langdon SP et al. Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One 2011; 6: e23772.
20. Buzza MS, Netzel-Arnett S, Shea-Donohue T, Zhao A, Lin CY, List K et al. Membraneanchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine. Proc Natl Acad Sci USA 2010; 107: 4200-4205.
21. Guy GR, Wong ES, Yusoff P, Chandramouli S, Lo TL, Lim J et al. Sprouty: how does the branch manager work? J Cell Sci 2003; 116: 3061-3068.
22. Li X, Brunton VG, Burgar HR, Wheldon LM, Heath JK, FRS2-dependent SRC. activation is required for fibroblast growth factor receptor-induced phosphorylation of Sprouty and suppression of ERK activity. J Cell Sci 2004; 117: 6007-6017.
23. DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. Regulation of Sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol 2006; 26: 1898-1907.
24. Edwin F, Anderson K, Patel TB. HECT domain-containing E3 ubiquitin ligase Nedd4 interacts with and ubiquitinates Sprouty2. J Biol Chem 2010; 285: 255-264.
25. Dhawan P, Singh AB, Deane NG, No Y, Shiou S-R, Schmidt C et al. Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 2005; 115: 1765-1776.
26. Lee M, Vasioukhin V. Cell polarity and cancer - cell and tissue polarity as a non-canonical tumor suppressor. J Cell Sci 2008; 121: 1141-1150.
27. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537-544.
28. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009; 175: 1453-1463.
29. van der Gun BT, Huisman C, Stolzenburg S, Kazemier HG, Ruiters MH, Blancafort P et al. Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer. Br J Cancer 2013; 108: 881-886.
30. Lei Z, Maeda T, Tamura A, Nakamura T, Yamazaki Y, Shiratori H et al. EpCAM contributes to formation of functional tight junction in the intestinal epithelium by recruiting claudin proteins. Dev Biol 2012; 371: 136-145.
31. Wu CJ, Mannan P, Lu M, Udey MC. Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions. J Biol Chem 2013; 288: 12253-12268.
32. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011; 121: 1064-1074.
33. Warzecha CC, Carstens RP. Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Semin Cancer Biol 2012; 22: 417-427.
34. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011; 300: 66-78.
35. Horiguchi K, Sakamoto K, Koinuma D, Semba K, Inoue A, Inoue S et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2012; 31: 3190-3201.
36. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, Schreiber M et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2007; 26: 6979-6988.
37. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
38. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
39. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
40. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
41. Ozaki K, Miyazaki S, Tanimura S, Kohno M. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci 2005; 118: 5861-5871.
42. Dave N, Guaita-Esteruelas S, Gutarra S, Frias A, Beltran M, Peiro S et al. Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J Biol Chem 2011; 286: 12024-12032.
43. Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer 2012; 12: 23-38.
44. Bornholdt J, Friis S, Godiksen S, Poulsen SS, Santoni-Rugiu E, Bisgaard HC et al. The level of claudin-7 is reduced as an early event in colorectal carcinogenesis. BMC Cancer 2011; 11: 65.
45. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T et al. Defective claudin-7 regulation by Tcf-4 and Sox-9 disrupts the polarity and increases the tumorigenicity of colorectal cancer cells. Cancer Res 2008; 68: 4258-4268.
46. Nakayama F, Semba S, Usami Y, Chiba H, Sawada N, Yokozaki H. Hypermethylation-modulated downregulation of claudin-7 expression promotes the progression of colorectal carcinoma. Pathobiology 2008; 75: 177-185.
47. Merikallio H, Kaarteenaho R, Paakko P, Lehtonen S, Hirvikoski P, Makitaro R et al. Zeb1 and twist are more commonly expressed in metastatic than primary lung tumours and show inverse associations with claudins. J Clin Pathol 2011; 64: 136-140.
48. Swat A, Dolado I, Rojas JM, Nebreda AR. Cell density-dependent inhibition of epidermal growth factor receptor signaling by p38alpha mitogen-activated protein kinase via Sprouty2 downregulation. Mol Cell Biol 2009; 29: 3332-3343.
49. Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y et al. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012; 31: 4923-4934.
50. de Alvaro C, Martinez N, Rojas JM, Lorenzo M. Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell 2005; 16: 4454-4461.
51. Kohno Y, Okamoto T, Ishibe T, Nagayama S, Shima Y, Nishijo K et al. Expression of claudin7 is tightly associated with epithelial structures in synovial sarcomas and regulated by an Ets family transcription factor, ELF3. J Biol Chem 2006; 281: 38941-38950.
52. Aguilera O, Pena C, Garcia JM, Larriba MJ, Ordonez-Moran P, Navarro D et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 2007; 28: 1877-1884.
53. Punzon I, Criado LM, Serrano A, Serrano F, Bernad A. Highly efficient lentiviralmediated human cytokine transgenesis on the NOD/Scid background. Blood 2004; 103: 580-582.
54. Silva-Vargas V, Lo Celso C, Giangreco A, Ofstad T, Prowse DM, Braun KM et al. Betacatenin and Hedgehog signal strength can specify number and location of hair follicles in adult epidermis without recruitment of bulge stem cells. Dev Cell 2005; 9: 121-131.
55. 3a to promote metastasis in colon cancer. Nat Med 2012; 18: 892-901.
56. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
57. Risueno A, Fontanillo C, Dinger ME, De Las Rivas J. GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAs. BMC Bioinform 2010; 11: 221.
58. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2010.
59. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
60. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001; 125: 279-284.
61. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.